Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 5Terminated 4Recruiting 3Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 5NIH 4INDUSTRY 3

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 2Gastrointestinal 2Sarcoma 1

Conditions

Melanoma 49Breast Neoplasms 47Neoplasms 39Leukemia, Lymphocytic, Chronic, B-Cell 37Carcinoma, Non-Small-Cell Lung 36Neoplasm Metastasis 29Lymphoma, Large B-Cell, Diffuse 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Brain Neoplasms 24Lymphoma, Follicular 23Lung Neoplasms 23Colonic Neoplasms 23Rectal Neoplasms 22Carcinoma, Renal Cell 22Lymphoma, Non-Hodgkin 21Prostatic Neoplasms 20Glioblastoma 20Leukemia, Myeloid, Acute 19Kidney Neoplasms 19Pancreatic Neoplasms 18Lymphoma, B-Cell, Marginal Zone 18Lymphoma, Mantle-Cell 17Gliosarcoma 17Burkitt Lymphoma 17Sarcoma 16Multiple Myeloma 16Waldenstrom Macroglobulinemia 15Ovarian Neoplasms 15Esophageal Neoplasms 15Lymphoma 14

Interventions

Celecoxib 2saracatinib 1FANG vaccine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × NIH × Thymoma × Clear all
NCT01143545 2020-03-03

Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
10 enrolled
GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Esophageal Neoplasms, Lung Neoplasms, Sarcoma, Thymoma

NCT01258868 2019-12-03

Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
44 enrolled
GastrointestinalOther solid neoplasmThoracic

Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymoma

NCT01100944 2017-08-10

A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
26 enrolled 33 charts
Thoracic

Thymoma, Thymus Neoplasms

NCT00718809 2015-06-10

Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
21 enrolled 13 charts
Thoracic

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡